Anti-retroviral effects of interferon-alpha in AIDS-associated Kaposi's sarcoma - PubMed (original) (raw)

Clinical Trial

. 1988 Nov 26;2(8622):1218-22.

doi: 10.1016/s0140-6736(88)90811-2.

Affiliations

• PMID: 2903954
• DOI: 10.1016/s0140-6736(88)90811-2

Free article

Clinical Trial

Anti-retroviral effects of interferon-alpha in AIDS-associated Kaposi's sarcoma

H C Lane et al. Lancet. 1988.

Free article

Abstract

21 patients with AIDS and Kaposi's sarcoma were enrolled in an open therapeutic trial to determine the in vivo anti-retroviral activity of recombinant interferon-alpha (IFN-alpha). 8 (38%) showed a complete or partial anti-tumour response. The mean pretreatment CD4 count for the responders was 399 cells/microliter vs 154 cells/microliter for the non-responders. All 5 of the patients with more than 400 CD4 cells/microliter pretreatment showed a significant reduction in tumour, whereas none of the 7 patients with under 150 CD4 cells/microliter had any response. 5 of the 6 complete or partial responders with greater than 50 pg/ml of human immunodeficiency virus (HIV) p24 before IFN therapy showed a 75% or greater reduction by 12 weeks of therapy, with 3 patients having persistently negative HIV cultures. The anti-viral effects were also most pronounced in the patients with the highest CD4 counts. These data demonstrate the potential benefits, both anti-tumour and anti-retroviral, of treatment with IFN-alpha in the early stages of HIV infection and Kaposi's sarcoma.

PubMed Disclaimer

Similar articles

• Clinical and virological effects of high-dose recombinant interferon-alpha in disseminated AIDS-related Kaposi's sarcoma.
  de Wit R, Schattenkerk JK, Boucher CA, Bakker PJ, Veenhof KH, Danner SA. de Wit R, et al. Lancet. 1988 Nov 26;2(8622):1214-7. doi: 10.1016/s0140-6736(88)90810-0. Lancet. 1988. PMID: 2903953
• Efficacy, safety, and tolerance of low-dose, long-term interferon-alpha 2b and zidovudine in early-stage AIDS-associated Kaposi's sarcoma.
  Mauss S, Jablonowski H. Mauss S, et al. J Acquir Immune Defic Syndr Hum Retrovirol. 1995 Oct 1;10(2):157-62. doi: 10.1097/00042560-199510020-00007. J Acquir Immune Defic Syndr Hum Retrovirol. 1995. PMID: 7552479
• Interferon-alpha with zidovudine: safety, tolerance, and clinical and virologic effects in patients with Kaposi sarcoma associated with the acquired immunodeficiency syndrome (AIDS).
  Krown SE, Gold JW, Niedzwiecki D, Bundow D, Flomenberg N, Gansbacher B, Brew BJ. Krown SE, et al. Ann Intern Med. 1990 Jun 1;112(11):812-21. doi: 10.7326/0003-4819-112-11-812. Ann Intern Med. 1990. PMID: 1971504 Clinical Trial.
• Interferon alpha in the treatment of AIDS-related Kaposi's sarcoma.
  Mitsuyasu RT. Mitsuyasu RT. Br J Haematol. 1991 Oct;79 Suppl 1:69-73. doi: 10.1111/j.1365-2141.1991.tb08124.x. Br J Haematol. 1991. PMID: 1931714 Review.
• AIDS-associated Kaposi's sarcoma and the mechanisms of interferon alpha's activity; a riddle within a puzzle.
  de Wit R. de Wit R. J Intern Med. 1992 Apr;231(4):321-5. doi: 10.1111/j.1365-2796.1992.tb00939.x. J Intern Med. 1992. PMID: 1588254 Review.

Cited by

• Endothelial Poldip2 regulates sepsis-induced lung injury via Rho pathway activation.
  Dolmatova EV, Forrester SJ, Wang K, Ou Z, Williams HC, Joseph G, Kumar S, Valdivia A, Kowalczyk AP, Qu H, Jo H, Lassègue B, Hernandes MS, Griendling KK. Dolmatova EV, et al. Cardiovasc Res. 2022 Aug 24;118(11):2506-2518. doi: 10.1093/cvr/cvab295. Cardiovasc Res. 2022. PMID: 34528082 Free PMC article.
• SARS-CoV-2 Portrayed against HIV: Contrary Viral Strategies in Similar Disguise.
  Duerr R, Crosse KM, Valero-Jimenez AM, Dittmann M. Duerr R, et al. Microorganisms. 2021 Jun 27;9(7):1389. doi: 10.3390/microorganisms9071389. Microorganisms. 2021. PMID: 34198973 Free PMC article. Review.
• People with HIV-1 demonstrate type 1 interferon refractoriness associated with upregulated USP18.
  Sugawara S, El-Diwany R, Cohen LK, Rousseau KE, Williams CYK, Veenhuis RT, Mehta SH, Blankson JN, Thomas DL, Cox AL, Balagopal A. Sugawara S, et al. J Virol. 2021 Apr 26;95(10):e01777-20. doi: 10.1128/JVI.01777-20. Epub 2021 Mar 3. J Virol. 2021. PMID: 33658340 Free PMC article.
• Cytokine-Targeted Therapeutics for KSHV-Associated Disease.
  Alomari N, Totonchy J. Alomari N, et al. Viruses. 2020 Sep 28;12(10):1097. doi: 10.3390/v12101097. Viruses. 2020. PMID: 32998419 Free PMC article. Review.
• The Potential of Immune Modulation in Therapeutic HIV-1 Vaccination.
  Seddiki N, Picard F, Dupaty L, Lévy Y, Godot V. Seddiki N, et al. Vaccines (Basel). 2020 Jul 27;8(3):419. doi: 10.3390/vaccines8030419. Vaccines (Basel). 2020. PMID: 32726934 Free PMC article. Review.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Elsevier Science

• Other Literature Sources

  • The Lens - Patent Citations Database

• Medical

  • MedlinePlus Health Information

• Research Materials

  • NCI CPTC Antibody Characterization Program